On July 19, 2023, Tenax Therapeutics, Inc. announced that the US Patent and Trademark Office has granted a new method of use patent for oral levosimendan (TNX-103) in the treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), which will expire in 2040.